For a significant portion of individuals grappling with persistent depressive disorders, conventional pharmacological interventions often fall short of delivering comprehensive relief, necessitating the exploration of advanced therapeutic modalities. Transcranial Magnetic Stimulation (TMS), a non-invasive technique that employs targeted magnetic pulses to modulate neural activity in brain regions associated with mood regulation, has emerged as a vital alternative for such patients. However, the traditional implementation of TMS typically mandates a rigorous commitment, requiring daily clinic visits for a protracted period, often spanning six to eight weeks. This demanding schedule can present substantial logistical hurdles for individuals managing concurrent professional responsibilities, family caregiving duties, transportation constraints, or pre-existing health conditions, thereby potentially limiting access to this beneficial treatment.
Despite these logistical challenges, TMS has established itself as a widely recognized and effective intervention for treatment-resistant depression. Extensive clinical research has demonstrated its capacity to significantly diminish depressive symptomatology in a substantial majority of patients, with reported success rates ranging from 60% to 70% experiencing symptom reduction, and a notable 25% to 35% achieving full remission. Furthermore, the widespread acceptance of TMS by most major insurance providers enhances its accessibility for eligible individuals, broadening its reach within the patient population.
In an effort to overcome the temporal barriers associated with conventional TMS protocols, researchers at UCLA Health embarked on an investigation into the feasibility of a substantially condensed treatment regimen. This novel approach, colloquially termed "five-by-five" or "5×5," involved administering five TMS sessions daily for a concentrated period of five consecutive days. The primary objective of this innovative strategy was to ascertain whether compressing the treatment timeline would still yield comparable therapeutic efficacy in alleviating depressive symptoms.
The findings derived from this groundbreaking study, subsequently published in the esteemed Journal of Affective Disorders, encompassed a cohort of 175 patients diagnosed with treatment-resistant depression. Within this group, 135 participants adhered to the established protocol, receiving one TMS session per day, five days a week, for a duration of six weeks. In parallel, a distinct group of 40 patients underwent the accelerated "5×5" format, comprising five daily sessions administered over a five-day span. Remarkably, both treatment cohorts exhibited significant reductions in their depressive symptom scores, with no statistically discernible disparities observed in the overall treatment outcomes between the standard and accelerated schedules.
Michael Apostol, a doctoral candidate at the UCLA Semel Institute for Neuroscience and Human Behavior and the lead author of the study, highlighted the critical importance of this accelerated approach. He articulated that the necessity of attending daily clinic appointments for an extended period of over six weeks often represents a formidable obstacle for individuals suffering from treatment-resistant depression. The study’s results, he explained, suggest a potential paradigm shift, offering these same patients a pathway to meaningful symptom improvement in less than a week by consolidating 25 TMS treatments into a mere five days.
A particularly compelling observation emerged concerning patients within the accelerated treatment group who did not exhibit pronounced symptom improvement immediately following the completion of their intensive five-day course. Subsequent evaluations conducted two to four weeks post-treatment revealed a substantial amelioration of depressive symptoms in these individuals, with their depression scores declining by an average of 36%. This finding underscores the crucial point that an immediate assessment of the efficacy of accelerated TMS, right at the conclusion of the five-day treatment period, may not fully encapsulate the totality of its therapeutic impact. It suggests that some patients who initially appear unresponsive may, in fact, experience significant and progressive benefits in the weeks that follow.
Dr. Andrew Leuchter, a distinguished professor and the director of the TMS Service within the UCLA Department of Psychiatry and Biobehavioral Sciences, and a senior author on the paper, emphasized this delayed response phenomenon. He noted that all participants in the study had previously failed to benefit from multiple trials of antidepressant medications, yet they still derived considerable advantage from the "5×5" treatment. Dr. Leuchter encouraged patients to maintain perseverance, advising them not to become disheartened if immediate relief is not perceived, as the benefits of the "5×5" protocol can continue to accrue and even intensify with an additional one to two days of treatment after a two-week interval.
While the accelerated "5×5" TMS protocol has yielded exceptionally promising results, it is important to acknowledge that the traditional six-week course demonstrated a more robust performance on certain long-term outcome measures. The researchers also prudently emphasized that this investigation was not designed as a randomized controlled trial, meaning that participants were not randomly allocated to either the standard or accelerated treatment groups. Consequently, further extensive and rigorously controlled studies are imperative to definitively validate these preliminary findings and solidify the evidence base for this expedited approach.
Beyond its application in treating depression, UCLA scientists are actively exploring the therapeutic potential of TMS for a range of other neurological and psychiatric conditions, including obsessive-compulsive disorder (OCD) and chronic pain management. As the scientific understanding and technological capabilities surrounding TMS continue to advance, this non-invasive neuromodulation technique is poised to play an increasingly prominent and transformative role in the evolving landscape of next-generation brain-based therapies for mental health and beyond.
About the Author
